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Abstract
The inner domain of the human immunodeficiency virus (HIV-1) gp120 glycoprotein has been proposed to mediate the noncovalent
interaction with the gp41 transmembrane envelope glycoprotein. We used mutagenesis to investigate the functional importance of a
conserved -sandwich located within the gp120 inner domain. Changes in aliphatic residues lining a hydrophobic groove on the surface of
the -sandwich decreased the association of the gp120 and gp41 glycoproteins. Other changes in the base of the hydrophobic groove resulted
in envelope glycoproteins that were structurally intact and able to bind receptors, but were inefficient in mediating either syncytium
formation or virus entry. These results support a model in which the -sandwich in the gp120 inner domain contributes to gp120–gp41
contacts, thereby maintaining the integrity of the envelope glycoprotein complex and allowing adjustments in the gp120–gp41 interaction
required for membrane fusion.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The human immunodeficiency virus (HIV-1) infects
cells that express the receptors, CD4, and either the CCR5
or the CXCR4 chemokine receptor (Dalgleish et al., 1984;
Klatzmann et al., 1984). Entry of HIV-1 into target cells is
mediated by the viral envelope glycoproteins, gp120 and
gp41 (Allan et al., 1985; Robey et al., 1985). The HIV-1
envelope glycoproteins are synthesized as an approximately
850- to 860-residue precursor, which assembles into trimers
(Earl et al., 1991). A complex of three gp160 glycoproteins
results from the addition of high-mannose and complex
sugars to the envelope glycoprotein precursor (Leonard et
al., 1990). Following proteolytic cleavage of gp160 in the
Golgi apparatus, the gp120 exterior envelope glycoproteins
remain associated with the gp41 transmembrane envelope
glycoproteins through noncovalent interactions (Helseth et
al., 1991). The mature envelope glycoprotein trimers are
transported to the cell surface, where they are incorporated
into budding virions. The gp120 envelope glycoprotein on
the virus binds CD4, which induces a conformational
change in gp120 that allows high-affinity binding to CCR5
or CXCR4 (Allan, 1991; Sattentau et al., 1993; Thali et al.,
1993; Trkola et al., 1996; Wu et al., 1996). Chemokine
receptor binding has been proposed to initiate another set of
conformational changes in the HIV-1 envelope glycopro-
teins, resulting in the exposure of the gp41 ectodomain to
the target cell membrane (Dalgleish et al., 1984; Klatzmann
et al., 1984). The gp41 transmembrane glycoprotein is
thought to be able to interact with the cell membrane and, by
forming an energetically favorable six-helix bundle, fuse
the viral and cell membranes (Chan et al., 1997; Lu et al.,
1995; Pinter et al., 1989; Weissenhorn et al., 1997). The
resulting pore allows access of the viral capsid to the cyto-
plasm of the target cell.
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The HIV-1 envelope glycoproteins assume multiple
conformations during the process of virus entry (Chan et
al., 1997; Lu et al., 1995; Weissenhorn et al., 1997; Wyatt
et al., 1998). Precise structural information is available
on only a few of these conformational states (Chan et al.,
1997; Kwong et al., 1998, 2000a; Lu et al., 1995; Weis-
senhorn et al., 1997). The X-ray crystal structure of the
HIV-1 gp120 core in a complex with soluble CD4 and the
Fab fragment of a neutralizing antibody has been deter-
mined for gp120 proteins derived from two different
HIV-1 strains (Kwong et al., 1998, 2000a). One strain,
HXBc2, has been adapted to grow on T cell lines, utilizes
the CXCR4 coreceptor, and is relatively sensitive to
neutralization by antibodies (Feng et al., 1996; Sullivan
et al., 1995). The other strain, YU2, was not passaged in
tissue-cultured cells, uses CCR5 as a receptor, and is
neutralization resistant (Leonard et al., 1990; Li et al.,
1992). Despite these differences, the structures of the
CD4-bound gp120 cores from these viruses are virtually
identical. In the CD4-bound conformation, the gp120
core consists of an inner domain, an outer domain, and a
connecting minidomain called the bridging sheet (Fig.
1A) (Kwong et al., 1998, 2000a). Based upon the expec-
tation that glycosylated and variable gp120 surfaces, as
well as the epitopes for neutralizing antibodies, are ac-
cessible on the HIV-1 envelope glycoprotein trimer, the
orientation of the gp120 core in the envelope glycopro-
tein complex has been modeled (Kwong et al., 2000b;
Wyatt et al., 1998). In these models, the gp120 inner
domain is proposed to mediate the noncovalent associa-
tion with the ectodomain of the gp41 transmembrane
glycoprotein. This labile interaction is susceptible to dis-
ruption by amino acid changes in the gp41 ectodomain or
in the N- and C-termini of gp120, which are thought to be
proximal in the HIV-1 envelope glycoprotein trimer
(Helseth et al., 1991; Ivey-Hoyle et al., 1991). Because
these N- and C-terminal segments were deleted from
gp120 to allow crystallization, their precise structure is
unknown (Kwong et al., 1998). Based on the location of
the truncated termini in the crystallized gp120 core, it is
likely that the complete N- and C-terminal portions of
gp120 lie adjacent to the inner domain. The gp120 inner
domain consists of a two-helix, two-strand bundle capped
by a small -sandwich (Kwong et al., 1998, 2000a). This
-sandwich is composed of two antiparallel -sheets, one
four-stranded and the other two-stranded. A hydrophobic
groove exists on the surface of this -sandwich. Of the
six strands (0, 1, 5, 6, 7, and 25) that constitute the
-sandwich, sequences in 5 and 25 appear to be con-
served in the exterior envelope glycoproteins of several
lentiviruses and some type A and B retroviruses (Hotzel
and Cheevers, 2001). Here we investigate the contribu-
tion of this conserved -sandwich to HIV-1 envelope
glycoprotein structure and function.
Results
HIV-1 envelope glycoprotein mutants with alterations in
the inner domain
Fig. 1A shows the domain structure of the HIV-1 gp120
core in the CD4-bound state. The four-on-two antiparallel
-sheets that compose the -sandwich in the HIV-1 gp120
inner domain are shown in detail in Fig. 1B. The residues
selected for alteration by mutagenesis are generally exposed
on the surface of the -sandwich and contribute to the
existence of a hydrophobic groove (Figs. 1B and 1C). One
residue, isoleucine 225, is not exposed on the gp120 surface,
but extends from the 5 strand in the base of the hydropho-
bic groove into the interior of the inner domain. The mutants
that were created and studied herein are listed in Table 1.
Expression of the HIV-1 envelope glycoprotein mutants
The expression of the wild-type and mutant HIV-1 YU2
envelope glycoproteins is shown in Fig. 2. The gp160 pre-
cursor protein and the gp120 exterior envelope glyco-
protein were evident in cells expressing the wild-type YU2
envelope glycoproteins. Shed gp120 was evident in the
supernatants of cells expressing the wild-type envelope gly-
coproteins. The mature gp120 glycoprotein was evident in
the lysates of cells expressing the E87I, A219V, A224S,
I225M, T244A, T244I, and Q246A mutants. Trace amounts
of the gp120 glycoproteins were seen in the lysates of cells
expressing the V489A and I491A envelope glycoproteins.
No gp120 glycoprotein was seen in the lysates of cells
expressing the V89A and L226A variants. As no gp120 was
detected in the supernatant of cells expressing the L226A
mutant, it appears that the change in leucine 226 results in
a major decrease in proteolytic processing of the gp160
envelope glycoprotein precursor. By contrast, the presence
of the mature gp120 glycoprotein in the supernatants of
cells expressing the V89A, V489A, and I491A variants
indicates that these envelope glycoproteins are processed,
but the gp120 does not associate efficiently with the gp41
transmembrane envelope glycoprotein. Minor effects of the
introduced amino acid changes on the stability of the
gp120–gp41 interaction were also evident for the A219V,
A224S, T244I, and Q246A mutants. These results indicate
that some changes in the -sandwich of the gp120 inner
domain decrease the efficiency of gp120–gp41 association.
Syncytium-forming ability of the HIV-1 envelope
glycoprotein mutants
To examine the ability of the envelope glycoprotein
mutants to form syncytia, 293T cells expressing these pro-
teins were cocultivated with Cf2Th-CD4/CCR5 cells, which
express both receptors utilized by the YU2 envelope glyco-
proteins (Choe et al., 1996). Fig. 3 shows that, under the
conditions of the assay, approximately 50 syncytia were
118 X. Yang et al. / Virology 313 (2003) 117–125
formed by the wild-type YU2 envelope glycoproteins. By
contrast, no syncytia were seen after cocultivation of
Cf2Th-CD4/CCR5 cells with mock-transfected 293T cells.
The E87I, A219V, A224S, T244A, Q246A, V489A, and
I491A envelope glycoproteins all formed syncytia at a level
of efficiency comparable to that of the wild-type YU2 en-
velope glycoproteins. Syncytium formation by the V89A
mutant was approximately 10% of that of the wild-type
envelope glycoproteins. Syncytium formation by the
I225M, L226A, and T244I envelope glycoproteins was ex-
tremely inefficient. These results indicate that, under the
conditions of our syncytium formation assay, membrane-
Fig. 1. The -sandwich in the HIV-1 gp120 inner domain. (A) The C tracing of the HXBc2 HIV-1 gp120 core (red, yellow, and green) and two-domain
CD4 (blue) is shown, based on the 2.2-Å resolution structure (Kwong et al., 2000a). In this orientation, the viral membrane would be near the top of the figure
and the target cell membrane near the bottom. The gp120 core domains are depicted: inner domain (red), outer domain (yellow), and bridging sheet (green).
The area in the white box, which contains the inner domain -sandwich, is shown in detail in B. (B) The individual -strands in the inner domain -sandwich
and the amino acid residues altered in this study are labeled. The color of the residue indicates the dominant phenotype associated with its alteration: yellow,
wild-type; red, subunit dissociation; green, membrane fusion defects; and blue, processing defects. The side chains of residues implicated in subunit
association or membrane fusion are shown. (C) The molecular surface of the inner domain -sandwich is shown, from the same orientation as in A and B.
The surfaces associated with valine 89, valine 489, and isoleucine 491 are colored red, and the surface of threonine 244 is colored green. Note that isoleucine
225 is buried and not surface-accessible. The images in A and B were made with MidasPlus (Computer Graphics Laboratory, University of California, San
Francisco) and the image in C was made with GRASP (Nicholls et al., 1991).
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fusing capacity of the YU2 envelope glycoproteins can be
quite efficient even when gp120–gp41 association is weak.
Thus, the low syncytium-forming ability of the I225M and
T244I mutants is not solely a result of changes in the
efficiency of processing or subunit association of these
envelope glycoproteins.
Ability of mutant envelope glycoproteins to support HIV-1
infection
The ability of the wild-type and mutant YU2 envelope
glycoproteins to mediate a single round of infection of
Cf2Th-CD4/CCR5 target cells was measured. The results in
Fig. 4 show that significant luciferase activity was detected
in Cf2Th-CD4/CCR5 cells exposed to the viruses with the
wild-type YU2 envelope glycoproteins. By contrast, the
luciferase activity in Cf2Th-CD4/CCR5 cells incubated
with viruses lacking envelope glycoproteins was less than
one luciferase unit (data not shown). Luciferase activity
comparable to that seen for the wild-type virus was detected
in cells incubated with viruses containing the E87I, A219V,
A224S, I225M, and Q246A envelope glycoproteins. Inter-
mediate levels of infection were associated with viruses
bearing the T244A and V489A envelope proteins. Infection
levels were low or undetectable for viruses with the V89A,
L226A, T244I, and I491A envelope glycoproteins. As ex-
pected, the envelope glycoproteins that exhibited very poor
processing (L226A) or subunit association (V89A and
I491A) did not efficiently support HIV-1 entry. Of note, the
capacity of the T244A, V489, and I491A mutants to support
infection was less than the syncytium-forming ability of
these mutants. Conversely, although the I225M change did
not appreciably affect virus entry, syncytium-forming abil-
ity was dramatically attenuated.
Receptor-binding ability of selected mutants
The selective defect in syncytium-forming capacity of
the I225M envelope glycoproteins prompted an examina-
tion of the receptor-binding ability of this mutant. Receptor
binding was also studied for the T244I mutant, which was
also functionally defective despite adequate expression of
processed, intact envelope glycoproteins. The radiolabeled
gp120 glycoproteins were examined for the ability to bind
CCR5 on the surface of Cf2Th-CCR5 cells in the presence
of excess soluble CD4. Precipitation of radiolabeled gp120
from the supernatants of cells expressing the wild-type,
A219V, T244I, and I225M with a mixture of sera from
HIV-1-infected individuals indicated that similar levels of
the gp120 glycoproteins were used for the sCD4 and CCR5
binding assays (left panel, Fig. 5A). The results in the right
panel of Fig. 5B indicated that the wild-type YU2 and the
A219V, T244I, and I225M gp120 glycoproteins bound to
the sCD4 and CCR5 receptors efficiently.
Fig. 2. Immunoprecipitation of wild-type and mutant HIV-1 YU2 envelope
glycoproteins. The wild-type (WT) and mutant YU2 envelope glycopro-
teins were expressed in 293T cells, which were radiolabeled with [35S]cys-
teine/methionine. The cell lysates and supernatants were precipitated by a
mixture of sera from HIV-1-infected individuals. The precipitates were
analyzed by SDS–PAGE. The gp160 envelope glycoprotein precursors and
mature gp120 glycoproteins are indicated. The right-most lane shows the
results obtained in cells expressing a soluble gp120 glycoprotein.
Table 1











Wild-type    
E87I    
V89A    
A219V    
A224S    
I225M    
L226A  NA  
T244A    
T244I    
Q246A    
V489A  /  
I491A  /  
a Envelope glycoprotein phenotypes are reported as follows: ,
greater than 80% of wild-type levels;, 30–80% of wild-type levels;,
5–29% of wild-type levels; , less than 5% of wild-type levels.
b The mutant YU2 envelope glycoproteins are designated by residue, using
the standard numbering scheme recommended by Korber et al. (1998), based
on the HXBc2 prototype strain. The amino acid in the wild-type YU2 gp120
sequence, in single-letter code, is to the left of the residue number, and the
amino acid that is substituted is to the right of the numeral.
c Processing of the gp120 envelope glycoprotein precursor was assessed by
comparing the ratio (gp120cell gp120supernatant)/gp160cell for the mutant and
wild-type envelope glycoproteins.
d The efficiency of subunit association was assessed by comparing the ratio
gp120cell/gp120supernatant for the mutant and wild-type envelope glycoproteins.
NA not applicable.
e Virus entry efficiency was assessed as described in Fig. 4 legend and under
Materials and methods.
f Syncytium formation was assessed as described in Fig. 3 legend and under
Materials and methods.
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Discussion
Despite the significant number of HIV-1 envelope gly-
coprotein mutants that have been created and analyzed, the
effects of variation in the -sandwich of the gp120 inner
domain have been largely unexplored, with a few excep-
tions discussed below. Based on primary sequence similar-
ities, it has been suggested that elements of this -sandwich,
specifically the 5 and 25 strands, are conserved among
lentivirus exterior envelope glycoproteins (Hotzel and
Cheevers, 2001). Such conservation implies an important
structural or functional role. We introduced a number of
residue changes into the gp120 -sandwich and character-
ized the resulting phenotypes (summarized in Table 1). We
found that alanine substitution for three aliphatic residues
(valine 89, valine 489, and isoleucine 491) resulted in dra-
matic decreases in the stability of the noncovalent associa-
tion between gp120 and gp41. These residues line a hydro-
phobic groove on the surface of the -sandwich (Figs. 1B
and C) and are either invariant or conservatively replaced in
primate immunodeficiency virus gp120 glycoproteins
(Kuiken et al., 1999). Our results suggest that this hydro-
phobic groove contributes to gp120–gp41 stability by in-
teracting directly with gp41 or with gp120 sequences miss-
ing from current X-ray structures (Kwong et al., 1998,
2000a) that are themselves important for gp41 contacts.
With respect to the latter possibility, changes in the gp120
segments adjacent in the linear sequence to the 0 and 25
strands have been shown to result in the dissociation of the
gp120 and gp41 glycoproteins (Helseth et al., 1991).
The V89A mutant, in keeping with its very low level of
gp120–gp41 association, did not form syncytia or support
virus entry efficiently. Surprisingly, the V489A and I491A
mutants, which exhibit a low but detectable level of gp120–
gp41 association, formed syncytia as efficiently as the wild-
type YU2 envelope glycoproteins. Virus entry mediated by
these envelope glycoproteins was less efficient than that
associated with the wild-type envelope glycoproteins, but
was still substantial. How is it that such structurally labile
envelope glycoproteins retain a measure of function, partic-
ularly in syncytium formation? One reasonable explanation
is that the V489A and I491A changes introduce instability
Fig. 3. Syncytium formation by the wild-type and mutant HIV-1 envelope glycoproteins. 293T cells expressing the indicated envelope glycoproteins were
cocultivated with Cf2Th-CD4/CCR5 cells, and the syncytia were scored as described under Materials and methods. The means and standard deviations of
quadruplicate assays are reported.
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into the envelope glycoproteins that results in a faster rate of
gp120 shedding. The consequences of such instability are
expected to be greater in assays involving longer times
between envelope glycoprotein synthesis and the assess-
ment of phenotype. Both the overnight radiolabeling of
envelope glycoprotein-expressing cells and the production
and testing of viruses with these envelope glycoproteins
involve such circumstances. By contrast, in the syncytium
formation assay, freshly synthesized envelope glycoproteins
have opportunities to interact with receptor-bearing target
cells soon after transport to the cell surface. Thus, syncy-
tium formation would be expected to be less sensitive to a
time-dependent dissolution of the functional envelope gly-
coprotein complex.
The I225M mutant exhibited efficient precursor process-
ing, subunit association, receptor binding, and ability to
mediate virus entry. Yet, syncytium formation by this mu-
tant was almost completely attenuated. The same pheno-
types, wild-type levels of viral infection and greatly reduced
syncytium formation, were observed in the context of a
replication-competent virus infecting human peripheral
Fig. 4. Ability of wild-type and mutant YU2 envelope glycoproteins to complement virus entry. HIV-1 vectors encoding luciferase and pseudotyped with
the indicated envelope glycoproteins were incubated for 6 h with Cf2Th-CD4/CCR5 cells as described under Materials and methods. After washing and
culturing for 48 h, the cells were lysed and assayed for luciferase activity. The means and standard deviations of duplicate experiments are reported.
Fig. 5. Ability of wild-type and mutant YU2 envelope glycoproteins to
bind the CD4 and CCR5 receptors. The [35S]met/cys-labeled wild-type and
mutant YU2 gp120 glycoproteins from 293T cell supernatants were im-
munoprecipitated with pooled sera from HIV-1-infected individuals (left).
The HIV-1 gp120 glycoproteins were incubated with Cf2Th-CCR5 cells in
the presence of sCD4, and the bound gp120 glycoproteins were detected by
precipitation of cell lysates with pooled sera from HIV-1-infected individ-
uals. The bound gp120 glycoproteins are shown in the right panel.
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mononuclear cells (PBMC) (data not shown). Most HIV-1
strains have an isoleucine at gp120 residue 225, although
rare isolates such as 89.6 have a methionine at this position
(Reimann et al., 1996). Of interest, passage of a simian-
human immunodeficiency virus (SHIV) containing the 89.6
envelope glycoproteins in monkeys resulted in a more
pathogenic virus capable of rapidly depleting CD4-positive
T lymphocytes (Karlsson et al., 1997; Reimann et al., 1996).
The envelope glycoproteins of the passaged virus were
more efficient in forming syncytia than the parental 89.6
envelope glycoproteins (Etemad-Moghadam et al., 2001).
One of the changes in the envelope glycoproteins that spec-
ified this increase in syncytium-forming ability was a con-
version of methionine 225 to isoleucine (Etemad-Mo-
ghadam et al., 2000). Subsequent studies suggested the
importance of this change to the rapid CD4 T-lymphocyte-
depleting ability of the passaged SHIV (Etemad-Moghadam
et al., 2001). Our studies indicate that changes in residue
225 can modulate syncytium-forming ability in contexts
other than that of the 89.6 envelope glycoproteins.
The mechanism whereby the alteration of gp120 residue
225 results in a decrease in syncytium formation is of
interest. Apparently some post-receptor-binding function of
the HIV-1 envelope glycoproteins is attenuated when a
methionine residue occupies that position. It is thought that
receptor binding acts as a trigger for the induction of con-
formational changes in gp41 that ultimately lead to the
fusion of viral and target cell membranes (Berger et al.,
1999). The location of residue 225 between the receptor-
binding regions and the putative gp41-interacting surface of
gp120 raises the question of whether the intramolecular
signaling triggered by receptor engagement may be defec-
tive in the I225M mutant. The resulting compromise in
envelope glycoprotein function is most evident in processes,
such as syncytium formation, that require multiple success-
ful trimer–target cell interactions. Virus entry, which pre-
sumably requires fewer fruitful envelope glycoprotein com-
plex–target cell interactions than syncytium formation, is
expected to be less sensitive to changes in the envelope
glycoproteins that partially compromise function. Although
we did not detect any defect in virus entry for the I225M
mutant of the YU2 envelope glycoproteins, in entry assays
where short incubation times of virus and cells were used, a
mild decrease in the infectivity of 89.6 variants with a
methionine at position 225 was observed (Karlsson et al.,
1997). This mild decrease in virus replication was not man-
ifest in most other contexts, including in vivo SHIV repli-
cation in monkeys (Etemad-Moghadam et al., 2000; Karls-
son et al., 1997).
Changes in threonine 244 resulted in envelope glyco-
proteins that underwent proteolytic processing efficiently
and exhibited at most minor decreases in subunit associa-
tion. Receptor binding was comparable to that of the wild-
type gp120. Nonetheless, defects in either syncytium for-
mation or virus entry were evident. The T244A change is
more conservative and did not apparently affect syncytium-
forming ability, but did cause a significant reduction in virus
entry. The less conservative isoleucine substitution at posi-
tion 244 resulted in a complete loss of ability to form
syncytia and to mediate virus entry. The mild decrease in
subunit association seen for the T244I mutant seems un-
likely to account for this drastic diminution of function, as
mutants A219V and A224S exhibit similar levels of gp120–
gp41 association but are fully functional in virus entry and
syncytium formation assays. Thus, it appears that T244I is
defective in a post-receptor-binding step in envelope glyco-
protein function. It is noteworthy that both residues impli-
cated in promotion of the processes leading to membrane
fusion, i.e., threonine 244 and isoleucine 225, are located in
the base of the hydrophobic groove in the -sandwich
surface (Figs. 1B and C). Threonine 244 and isoleucine 225
reside on the adjacent, antiparallel 7 and 5 strands, re-
spectively. The isoleucine 225 side chain is situated in the
interior of the inner domain and is directed toward the
receptor-binding regions, whereas the threonine 244 side
chain is directed toward the expected location of the gp41
ectodomain. Isoleucine 225 may play a role in modulating
the position of the -sheet in response to receptor binding;
such conformational changes may in turn be transmitted to
gp41 via threonine 244. Further work will be required to
verify this model and to define the role of the conserved
inner domain -sandwich in HIV-1 envelope glycoprotein
function.
Materials and methods
Plasmids expressing HIV-1 envelope glycoproteins
The wild-type YU2 envelope glycoproteins were ex-
pressed from the pSVIIIenv vector, as previously described
(Sullivan et al., 1995). Plasmids expressing the YU2 enve-
lope glycoprotein mutants were created by standard Quick-
Change (Stratagene) protocols. All constructs were se-
quenced to confirm the presence of the desired mutation and
the absence of unintended coding changes.
Immunoprecipitations
The pSVIIIenv plasmid was cotransfected with a plasmid
expressing the HIV-1 Tat protein into 293T cells, using
LipofectAMINE reagent (Invitrogen) according to the man-
ufacturer’s recommendations. Beginning at approximately
24 h after transfection, the cells were labeled with 200 Ci
each of [35S]methionine/cysteine in methionine/cysteine-
free medium overnight. The culture medium was then har-
vested after centrifuging at 2500 rpm for 10 min. The
labeled cells were washed with 5 ml PBS and stripped from
the plates with 10 mM EDTA/PBS. The harvested cells
were lysed in 1 ml lysis buffer [20 mM Tris–HCl, pH 7.4,
0.5 M NaCl, 0.5% NP-40, and 1 protease inhibitor cock-
tail (Pharmacia)] for 30 min at 4°C. Cell lysates were
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collected after clearing the cell debris by centrifugation at
14,000 rpm in an Eppendorf microfuge for 30 min at 4°C.
For the immunoprecipitations, 400 l of media or cell
lysates were incubated overnight at 4°C with 3 l of pooled
sera from HIV-1-infected individuals and 50 l Protein
A–Sepharose (10% w/v in PBS) (Pharmacia) that had been
preincubated with 5% bovine serum albumin in PBS. After
three washes with 1 ml lysis buffer, the beads were boiled
for 5 min in 1 SDS-sample buffer with 2% -mercapto-
ethanol. The protein samples were then analyzed on 7.5%
SDS–polyacrylamide gels (Ready-Gel, Bio-Rad).
CD4 and CCR5 binding assays
The wild-type YU2 gp160 and a selected panel of mu-
tants were expressed in 293T cells and labeled with
[35S]met/cys as described above. Next, 400 l of the super-
natants with [35S]met/cys-labeled HIV-1 gp120 glycopro-
teins were immunoprecipitated with pooled sera of HIV-1-
infected individuals to quantify the amounts of protein to be
used for the receptor-binding assays. Approximately 1.5 ml
of these supernatants were concentrated 10-fold using Cen-
triprep YM-30 (Amicon). Cf2Th-CCR5 cells were har-
vested from tissue culture flasks by incubating with 10 mM
EDTA/PBS and washed once with 5 ml of PBS. The con-
centrated supernatants and 2 106 Cf2Th-CCR5 cells were
then mixed with 3 g of sCD4. The binding mixture was
incubated at 37°C for 1 h with occasional shaking. The
binding was terminated by three washes of 1 ml PBS. The
cell-bound HIV-1 envelope glycoproteins were then ex-
tracted using the cell lysis buffer and detected by immuno-
precipitation, using conditions as described above.
Syncytium formation assay
Plasmids expressing the wild-type or mutant YU2 enve-
lope glycoproteins were transfected into 293T cells, using
LipofectAMINE reagent (Invitrogen) according to the man-
ufacturer’s protocol. After 24 h, the cells were harvested by
treatment with 10 mM EDTA/PBS. Approximately 2  103
transfected 293T cells were added to each well of a 96-well
plate that had been seeded the night before with 6  103
Cf2Th-CD4/CCR5 cells. The Cf2Th-CD4/CCR5 cells are
canine thymocytes that express human CD4 and CCR5
(Farzan et al., 1999). After 6 h at 37°C, the syncytia, which
were defined as cells with five or more nuclei, were counted.
For each envelope glycoprotein variant, quadruplicate wells
were scored and the mean value reported.
Single-round infection assay
Recombinant HIV-1 encoding luciferase and pseudotyped
with the wild-type or mutant YU2 envelope glycoproteins was
produced as previously described (Hofmann et al., 1999).
Briefly, 293T cells in 100-mm tissue culture dishes were co-
transfected by the calcium phosphate technique with 2.5 g
pSVIIIenv plasmid expressing the HIV-1 envelope glycopro-
tein variants, 5g of the pCMV-PACK plasmid expressing the
Gag/Pol and Tat proteins of HIV-1, and 15 g of pHIV-1-Luc,
which expresses an HIV-1 vector with a firefly luciferase
reporter gene. Three days after transfection, the recombinant
virions in the cell supernatants were harvested and quantitated
by measuring the reverse transcriptase activity by 3H-TTP
incorporation. Approximately 6  103 Cf2Th-CD4/CCR5
cells were seeded into each well of a 96-well luciferase assay
plate (EG&G Wallac) and cultured at 37°C with 5% CO2
overnight. For each assay, 5000 reverse transcriptase units of
the virus stock were incubated with the target cells for 6 h at
37°C. After washing, the cells were cultured for another 48 h
and then lysed and used for measurement of luciferase activity.
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